Biodegradable Polyester Nanoparticle Vaccines Deliver Self‐Amplifying mRNA in Mice at Low Doses

Abstract

Delivery of self-amplifying mRNA (SAM) has high potential for infectious disease vaccination due to its self-adjuvanting and dose-sparing properties. Yet a challenge is the susceptibility of SAM to degradation and the need for SAM to reach the cytosol fully intact to enable self-amplification. Lipid nanoparticles are successfully deployed at incredible speed for mRNA vaccination, but aspects such as cold storage, manufacturing, efficiency of delivery, and the therapeutic window can benefit from further improvement. To investigate alternatives to lipid nanoparticles, a class of >200 biodegradable end-capped lipophilic poly(beta-amino ester)s (PBAEs) that enable efficient delivery of SAM in vitro and in vivo as assessed by measuring expression of SAM encoding reporter proteins is developed. The ability of these polymers to deliver SAM intramuscularly in mice is evaluated, and a polymer-based formulation that yields up to 37-fold higher intramuscular (IM) expression of SAM compared to injected naked SAM is identified. Using the same nanoparticle formulation to deliver a SAM encoding rabies virus glycoprotein, the vaccine elicits superior immunogenicity compared to naked SAM delivery, leading to seroconversion in mice at low RNA injection doses. These biodegradable nanomaterials may be useful in the development of next-generation RNA vaccines for infectious diseases.

Charge neutralized poly(β-amino ester) polyplex nanoparticles for delivery of self-amplifying RNA

“…In this study we aimed to evaluate the effects of added polyanions to polycation/saRNA complexes, as prior studies had shown that mixed polycation/polyanion systems could transfect certain cancer cells in vitro and in vivo with greater efficacy for pDNA and with siRNA than the binary polycation nucleic acid complexes alone. 35 For assays with saRNA we made the specic choices of poly(b-amino-ester)s (PBAEs) as the polycations as these have been shown to be effective delivery agents for saRNA in pre-clinical studies, 36 and poly(glutamic acid)s (PGAs) owing to their known safety prole and ready availability. [37][38][39] The versatility of the routes to PBAEs and the ease of end-group modication via the nal capping stage has been exploited by many groups, with a range of chemistries adopted and with or without cell-targeting agents.…”